Comparison Between Neutrophil–Lymphocyte Ratio and Systemic Immune-Inflammation Index as Predictors of One-Year Survival in Patients with Untreated Advanced Hepatocellular Carcinoma

• DOI: 10.1007/s12029-021-00796-7
• Publication Date: 2022-01-31T08:03:55Z
• Authors: Irsan Hasan; Lutfie Lutfie; Ikhwan Rinaldi; Juferdy Kurniawan; Imelda Maria Loho
• Keywords: Youden's J statistic

Abstract Background Patients with hepatocellular carcinoma (HCC) generally only come for treatment when cancer has reached an advanced stage, with very limited treatment options. There has not been an accurate predictor marker to be able to identify which group of patients may have better survival. This study wanted to analyze the role of the inflammatory status indices as predictors of one-year survival in patients with advanced HCC who did not undergo therapy. Methods This study has a retrospective cohort design using secondary data on subjects with advanced HCC who did not undergo therapy at Cipto Mangunkusumo Hospital and Dharmais Hospital. The Neutrophil-lymphocyte ratio (NLR) and Systemic immune-inflammation index (SII) were evaluated for their role as predictors of one-year survival based on the Area Under Receiving Operator Curve (AUROC). The best optimal cutoff for NLR and SII was decided based on the Youden index, followed by survival analysis based on those cutoffs. Confounding factors were analyzed with multivariate cox regression analysis. Results A total of 196 subjects were included in the data analysis. One-year survival was 6.6%, with a median survival of 56 days (95% CI: 46-67). The NLR had a discriminatory ability based on AUROC of 0.667 (95% CI: 0.536-0.798; p = 0.044), with the optimal cut-off point to differentiate survival was 3.7513. The SII has a discriminatory ability based on AUROC of 0.766 (95% CI: 0.643-0.889; p = 0.001), with the optimal cut-off point to distinguish survival was 954.4782. SII had superiority in discriminatory ability (p = 0.0415). Conclusions The discriminatory ability based on AUROC of SII was better than that of NLR in predicting one-year survival in patients with advanced HCC who did not undergo therapy.